Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
June 12, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Michael Ulz reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
The Overweight rating by Morgan Stanley indicates a positive outlook for Silence Therapeutics. The maintained $20 price target suggests that the stock is expected to perform well in the short term. This news is likely to have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100